Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 47, Issue 5, 2013, Pages 629-631

  Benatar, Michael ^a   Wuu, Joanne ^a   Ravits, John ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ASYMPTOMATIC DISEASE; CLINICAL OBSERVATION; DISEASE COURSE; EDITORIAL; FRONTOTEMPORAL DEMENTIA; GENE; GENETIC RISK; GENETIC SCREENING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE REPEAT; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS;

EID: 84876787283     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23782     Document Type: Editorial

References (15)

1. Benatar M, Wuu J. Pre-symptomatic studies in ALS: rationale, challenges and approach. Neurology 2012;79:1732- 1739.
2. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;20:245- 256.
3. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257- 268.
4. Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:323- 338.
5. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:131- 146.
6. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11:323-330.
7. Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007;68:1571-1575.
8. Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 2007;68:1576- 1582.
9. Brooks B, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders 2000;1:293- 299.
10. Brooks BR. El Escorial World Federation of Neurology Criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96-107.
11. Rutkove S, Caress J, Cartwright M, Burns TM, Warder J, David WS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler 2012;13:439-445.
12. Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011;77:235-241.
13. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011;10:400-403.
14. Bak TH, Chandran S. What wires together dies together: verbs, actions and neurodegeneration in motor neuron disease. Cortex 2012;48:936-944.
15. Carew JD, Nair G, Andersen PM, Wuu J, Gronka S, Hu X, et al. Pre-symptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology 2011;77:1370-1375.